Although PALOMA-3 and MIRHO trials did not report an association between PIK3CA baseline status and PFS, it has been shown that BC PIK3CA-mutated patients treated with a combination of palbociclib and fulvestrant improves PFS [80,82]. Here, PIK3CA is linked to breast cancer.